

**PRODUCT INFORMATION**

<b>Common Name</b>	SGN-35, cAC10-Val-Cit-MMAE, Unconjugated mAb
<b>Synonyms</b>	TNFRSF8;CD30;D1S166E;Ki-1
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	ELISA; Flow Cyt
<b>Recommended Dilutions</b>	ELISA 1:5000-10000; Flow Cyt 1:100
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Host Species</b>	Chimeric
<b>IgG type</b>	IgG1
<b>Reactivity</b>	Human
<b>Target</b>	CD30
<b>Uniprot ID</b>	P28908
<b>Description</b>	Anti-CD30 (brentuximab biosimilar) mAb
<b>Delivery</b>	In Stock
<b>Storage &amp; Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.
<b>Usage</b>	Research use only
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.



## Anti-CD30 (brentuximab biosimilar) mAb ELISA

0.2 µg of CD30, His Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 µg/ml (100 µL/well) Human CD30, His tagged protein (PME100481) can bind Anti-CD30 Neutralizing antibody in a linear range of 0.13-80.0 ng/ml.




Figure 2. Flow cytometry analysis with Anti-CD30 (brentuximab ) on Expi293 cells transfected with human CD30 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).






Figure 3. Flow cytometry analysis of antigen binding of anti-human CD30 mAb(BME100017).  
(A) A clear peak shift of BME100017 was seen compared to the control when incubated with CD30-expressing 8226 cells, indicating strong binding of BME100017 to CD30. Antibodies were incubated at 2  $\mu\text{g}/\text{mL}$ .

DIMABIO CONFIDENTIAL

